EuroBiotech: More Articles of Note


> Rottapharm Biotech shared phase 2 data on CR4056 in chronic pain associated with osteoarthritis. The trial missed its primary endpoint but generated results to encourage Rottapharm that the drug works in patients with a certain phenotype. Release 

> Themis Bioscience began a phase 1 trial of its Zika virus vaccine. Statement 

> Eisai struck a deal with Numab top develop multispecific antibody cancer immunotherapies. Numab will receive an upfront payment plus milestones. Release  


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Novo Holdings and Arix Bioscience co-led a €20 million ($22 million) series A financing in STipe Therapeutics. The funding will support efforts to modulate the STING pathway. Statement 

> Genfit appointed Dean Hum as president of its U.S. operation. Hum is relocating to the U.S. Release  

> Transgene shared clinical data on TG4001 in combination with Merck KGaA and Pfizer’s anti-PD-L1 immunotherapy. Three of the six HPV-positive cancer patients who received the higher dose of therapeutic vaccine TG4001 experienced durable partial responses. Statement 

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.